Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
23,630 total articles
Eikon Therapeutics announced the appointment of Dr. Ching-Pin Chang as Executive Vice President and Chief Scientific Officer. Dr. Chang brings over 20 years of experience in academic medicine and biopharmaceutical drug discovery, having held key roles at Bristol Myers Squibb, Gilead Sciences, and MyoKardia. His extensive expertise in translational …
Trevi Therapeutics announced that senior executives will participate in several major healthcare and IPF-related conferences in September 2026, presenting updates on their investigational therapy Haduvio™ (oral nalbuphine ER) intended to treat chronic cough associated with IPF, non-IPF ILD, and refractory chronic cough. The company highlighted the …
Dyne Therapeutics announced preclinical data supporting the development of four novel investigational therapies targeting Duchenne Muscular Dystrophy (DMD) mutations amenable to exon skipping of 44, 45, 53, and 55. These candidates, based on the same FORCE™ platform as their lead drug under FDA review, demonstrated promising in vitro and in vivo re…
Saia, Inc. releases its less-than-truckload (LTL) shipment and tonnage data for July and August 2026, showing increases in shipments per workday, tonnage per workday, and weight per shipment compared to the same months in 2025. These gains indicate solid operational performance in the third quarter so far, though the company cautions actual results…
Alterity Therapeutics, a biotechnology company focused on neurodegenerative diseases, announced that CEO David Stamler will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026. The company is preparing for a Phase 3 pivotal trial for its lead drug ATH434, which has shown promising results in Phase 2 trials for Multiple Sy…
Amwell received Frost & Sullivan's 2026 Technology Innovation Leadership Recognition for its unified technology platform that addresses healthcare fragmentation by integrating consumer experiences, clinician workflows, care programs, and partner solutions. The award highlights Amwell’s innovation and business impact in creating a connected infrastr…
GXO Logistics, Inc. has expanded its technology organization by appointing Balaji Rangaswamy as Chief Information Officer. The restructuring focuses on enhancing the company's enterprise systems to support scalable growth and resilience while accelerating innovation, particularly in areas like AI and robotics. This move underlines GXO's commitment …
Avalo Therapeutics announced its participation in several upcoming investor conferences, including the Cantor Global Healthcare Conference and Morgan Stanley Annual Global Healthcare Conference. The company focuses on developing IL-1β pathway therapeutics for immune-mediated inflammatory diseases and is advancing its lead candidate, abdakibart, int…
Victoria's Secret & Co. reported a strong second quarter in 2026 with net sales increasing 10% to $1.611 billion, operating income rising to $257 million, and adjusted operating income surpassing guidance at $124 million. The company has raised its full-year 2026 net sales and adjusted operating income guidance, citing growth across all business se…
Breckenridge Distillery, a craft spirits brand under Tilray Brands, announced an expanded distribution partnership with Southern Glazer’s Wine & Spirits in New York and California. This expansion aims to increase market penetration and consumer access to its broad portfolio including bourbon, vodka, and ready-to-drink offerings in two of the larges…
Climb Bio announced positive Phase 1 trial data for its anti-APRIL monoclonal antibody, CLYM116, showing a ~29-day half-life and sustained APRIL suppression with favorable safety. The data supports an every-12-week dosing regimen for treating IgA nephropathy. The Phase 2 NAVIGATE-2 trial is ongoing with initial data expected in H1 2027, and a Phase…
LeonaBio, a clinical-stage biopharmaceutical company listed on NASDAQ, announced its participation in the Cantor Global Healthcare Conference 2026. Management will engage in a fireside chat to discuss their novel therapeutic developments targeting diseases with high unmet medical needs, including metastatic breast cancer and ALS. The event will fea…
C4 Therapeutics announced it will present new biomarker data demonstrating the immunomodulatory effects of its investigational drug cemsidomide, combined with dexamethasone, from its Phase 1 relapsed/refractory multiple myeloma trial at the 23rd International Myeloma Society Annual Meeting. The data highlights the drug's impact on T and NK cells, s…
Eledon Pharmaceuticals announced multiple milestones for its lead drug candidate tegoprubart, including IND submission to FDA for an islet cell transplantation trial, enrollment of first patients in investigator-initiated studies, compassionate use dosing in transplant patients with renal dysfunction and high sensitization, and reaffirmed plans to …
Fate Therapeutics announced management's participation in a fireside chat at the upcoming 2026 Annual Cantor Global Healthcare Conference to discuss its iPSC-derived off-the-shelf CAR T-cell product candidate FT819, recent clinical progress including the start of the Phase 2 RECLAIM-LN trial for lupus nephritis, and the unique safety profile of FT8…
Cartesian Therapeutics, a late clinical-stage biotech company focused on cell therapies for autoimmune diseases, announced its participation in several key investor conferences in September 2026, including Cantor Global Healthcare, Morgan Stanley Healthcare, and H.C. Wainwright. The company will discuss its lead CAR-T therapeutic candidates in vari…
Gyre Therapeutics, Inc., a commercial-stage biopharmaceutical company listed on Nasdaq, announced that its management will participate in two significant healthcare investor conferences in September 2026: the Cantor Global Healthcare Conference and the Morgan Stanley Healthcare Conference. The company focuses on developing small-molecule therapeuti…
BlossomHill Therapeutics, a clinical-stage biopharmaceutical company focused on innovative small molecule cancer treatments, will present at the 8th Annual RAS-Targeted Drug Development Summit and the H.C. Wainwright 28th Annual Global Investment Conference. The company highlighted its leading programs including BH-30643, a Fast Track designated dr…
Aurora Mobile Limited showcased its AI solution portfolio at the AI Expo Summer 2026 in Tokyo, featuring EngageLab, GPTBots.ai, and Modellix.ai platforms designed to enhance customer engagement, support automation, and AI media generation. The company's modular AI solutions attracted strong interest from multiple sectors including financial service…
ANI Pharmaceuticals announced its participation in three upcoming investor conferences in September 2026, where its CEO and leadership team will present and engage in discussions. The conferences include the Wells Fargo Healthcare Conference, Morgan Stanley Global Healthcare Conference, and H.C. Wainwright Annual Global Investment Conference. These…
The Scotts Miracle-Gro Company announced its intent to acquire Black Kow, an established brand in soil amendments, to expand its product portfolio and support its SMG 2.0 growth plan. The acquisition is expected to close in October 2026 and aims to drive topline sales growth, improve margins, and be accretive to earnings beginning in year one. This…
Pharvaris shared extensive translational, nonclinical, and clinical data on its oral bradykinin B2 receptor antagonist deucrictibant at the Bradykinin Symposium 2026, highlighting the drug's efficacy and safety in treating bradykinin-mediated angioedema. Results from Phase 2 and Phase 3 clinical studies demonstrated rapid and durable symptom relief…
Lands' End, Inc. (NASDAQ: LE) announced second quarter fiscal 2026 results highlighting a 2.7% increase in net revenue to $302 million driven by a 9% rise in U.S. eCommerce sales. The company reported net income of $3.5 million versus a loss in the prior year period, with gross margins improving by 320 basis points due in part to tariff refunds. Op…
Scorpio Tankers Inc. provided an update on its third quarter 2026 Time Charter Equivalent (TCE) rates across various vessel classes, highlighting robust daily revenues. The company also announced entering into three-year time charter-out agreements for three product tankers, with attractive daily rates commencing in the third and fourth quarters of…
Parsons Corporation announced that its Chair, President, and CEO, Carey Smith, along with CFO Matt Ofilos, will participate in a fireside chat at the 2026 Jefferies Global Industrials Conference on September 9, 2026. The session will be webcast live and available for replay, offering insights into Parsons' business and strategy.
